Attached files
 Business Segment
Review Third Quarter 2010
Earnings Call
October 27, 2010
Exhibit 99.2 |
 Table of
Contents Safe Harbor
1
Business Segments
2
Clinical Development Services
Laboratory Services
Net Revenue by Segment
3
Income from Operations by Segment
4 |
 Safe Harbor
This presentation includes selected non-GAAP financial
measures. For a presentation of and reconciliation to the
most directly comparable GAAP financial measures, go to
the link titled “GAAP/Non-GAAP Reconciliation
Presentation”
under Presentations & Events in the
Investors section of PPD’s
Web site
located at
www.ppdi.com
1 |
 Business
Segments *
Clinical Development Services
Phase II-IV Clinical Trial Management
-
Project Management
-
Clinical Trial Monitoring
-
Data Management
-
Biostatistics
-
Regulatory Affairs
-
Pharmacovigilance
-
Late-Stage
Laboratory Services
Phase I Clinic
cGMP
Bioanalytical
Global Central Labs
Vaccines & Biologics
BioDuro
/ Discovery Services
2
*These two segments comprise the former Development segment.
|
 Net Revenue by
Segment (Non-GAAP, in Millions*)
Q1
2009
Q2
2009
Q3
2009
Q4
2009
Q1
2010
Q2
2010
Q3
2010
Clinical Development Services
$268.1
$260.1
$250.0
$256.7
$249.3
$255.4
$260.3
% of Total
79.9%
78.8%
79.2%
78.2%
77.0%
76.5%
76.7%
Laboratory Services
$67.3
$70.1
$65.9
$71.4
$74.5
$78.3
$79.0
% of Total
20.1%
21.2%
20.8%
21.8%
23.0%
23.5%
23.3%
Total
(Formerly Development Segment)
$335.4
$330.2
$315.8
$328.1
$323.8
$333.8
$339.4
3
*Net revenue excludes reimbursed out-of-pockets.
|
 Income from
Operations by Segment (Non-GAAP, in Millions*)
Q1
2009
Q2
2009
Q3
2009
Q4
2009
Q1
2010
Q2
2010
Q3
2010
Clinical Development Services
$51.9
$48.0
$47.0
$41.0
$31.7
$34.6
$47.2
Operating Margin %
19.3%
18.5%
18.8%
16.0%
12.7%
13.6%
18.1%
Laboratory Services
$15.4
$15.2
$13.2
$12.8
$10.1
$12.3
$13.5
Operating Margin %
22.9%
21.7%
20.0%
17.9%
13.5%
15.6%
17.1%
Total
(Formerly Development Segment)
$67.3
$63.3
$60.2
$53.8
$41.8
$46.9
$60.7
Operating Margin %
20.1%
19.2%
19.0%
16.4%
12.9%
14.0%
17.9%
*Income from operations excludes reimbursed out-of-pocket
expenses, stock option expense, and restructuring costs. See
GAAP/Non-GAAP reconciliation in Investors section of PPD
website.
4 |